Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Mar 25;9:781888. doi: 10.3389/fmed.2022.781888

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2022 Agur, Ben-Dor, Herman-Edelstein, Steinmetz, Lichtenberg, Schneider, Yahav, Rozen-Zvi and Zingerman.

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

PMC Copyright notice

Antibody decay rate in hemodialysis patients following BNT162b2 vaccination. (A) S1-RBD-IgG level 3- and 6-months following 2nd dose of BNT162b2 vaccine in HD patients vs healthy controls. Results refer to HD group (n = 104) and control group (n = 21). * P-value < 0.001 using multivariate repeated ANOVA test. (B) S1-RBD antibody decay rate at 1-, 3- and 6- months following the 2nd dose of BNT162b2 vaccine in HD patients. A regression line was adjusted to the ln-transformed antibody level. Time to Ab level decay below 50 AU/ml - 259.54 days (95% CI 212.98 to 332.17). Results refer to HD group (n = 104).